Skip to content

Xencor XNCR Free cash flow margin

Free cash flow margin at other companies

Amgen logo
AmgenAMGN
23.1%-8.9pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.6%+5.5pp
Janux Therapeutics logo
Janux TherapeuticsJANX
-571.6%+98.3pp
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-238.9%-90.9pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
1.9%+1.0pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-3,732.2%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on trailing twelve months.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's free cash flow margin?
Xencor (XNCR) reported free cash flow margin of -194% in Q1 2026.
How has Xencor's free cash flow margin changed year-over-year?
Xencor's free cash flow margin decreased by 46.1% year-over-year, from -132.8% to -194%.
What is the long-term trend for Xencor's free cash flow margin?
Over 2 years (2022 to 2025), Xencor's free cash flow margin has grown at a 259.7% compound annual growth rate (CAGR), from -8.5% to -110.1%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.